LRRK2 and Parkinson disease: Notably, PD pathogenic mutations are clustered in the catalytic ROC-COR and kinase domain and lead to enhanced kinase activity [72–77], a key molecular hallmark of LRRK2 PD [78], which has attracted great attention from a therapeutic perspective (Clinical Trial ID:NCT03710707 [79], NCT04056689 [80]).